Stay up to date with the latest health and social care news from across the UK. From children’s mental health crisis and new inspection guidance for prison education to women’s mental health after childbirth and employment reforms affecting UK employers, discover the stories and developments shaping the sector.
New research into treatments for Alzheimer’s disease has renewed debate over whether medicines currently unavailable on the NHS could offer greater benefits to patients and families than previously recognised.
Two treatments, lecanemab and donanemab, have been licensed for use in the UK but have not been recommended for routine NHS funding in England because of concerns about their cost-effectiveness. Both target amyloid, a protein that accumulates in the brains of people with Alzheimer’s disease, and clinical trials have demonstrated that they can slow cognitive decline in some patients with early-stage disease.
The National Institute for Health and Care Excellence (NICE) previously concluded that the benefits were too modest to justify the substantial costs of providing the treatments, including specialist assessments, infusions and ongoing monitoring. Evidence considered by NICE suggested the medicines could delay progression from mild to moderate Alzheimer’s disease by approximately four to six months.
However, questions have been raised about whether traditional assessments adequately capture the wider value of slowing dementia, particularly the additional time patients may remain independent and the potential reduction in pressure on unpaid carers.
In March 2026, NICE agreed to reconsider its assessments of both medicines following an appeal which found that the wider effects on carers had not been adequately accounted for. Alzheimer’s Research UK welcomed the decision, arguing that the financial and emotional consequences of dementia extend far beyond the direct costs faced by the NHS.
For families supporting someone with Alzheimer’s, even a relatively modest delay in deterioration could mean additional months of independence, communication and participation in everyday activities. It could also potentially postpone the need for more intensive support, although the extent of any long-term benefit remains uncertain.
The debate is particularly relevant to social care, where dementia is a major driver of demand for homecare, residential care and unpaid family support. Treatments that meaningfully delay the progression of symptoms could have implications for care planning, workforce demand and the financial pressures facing families.
New five-year findings released by pharmaceutical company Eisai on 16 November suggest that the benefits of lecanemab may increase with continued treatment. The company reported that patients receiving the drug were less likely to progress to more advanced stages of Alzheimer’s than people in external comparison datasets. However, these longer-term findings were not based on a continuing randomised comparison with a placebo group, meaning they cannot establish the size of the treatment benefit with the same certainty as the original trial.
The findings also need to be considered alongside safety concerns. Anti-amyloid medicines can cause brain swelling and bleeding, and an independent 2026 review questioned whether the improvements seen across clinical trials were large enough to make a meaningful difference to patients.
The latest evidence will add to discussions about how new dementia treatments should be evaluated and funded. While lecanemab and donanemab are not cures, the possibility of slowing Alzheimer’s progression remains important for patients, families and the professionals supporting them.
Register with The Daily Round for the latest sector news, inspections & reports, wellbeing content, workforce insights, expert features and practical updates—delivered free to your inbox.
Posted by:
M Ramalani
Editorial Assistant – The Daily Round
Busy day? We’ve got you covered. Get FREE daily news, practical insights, opportunities and wellbeing content, carefully curated for busy health and social care professionals. Just enter your details below to get The Daily Briefing delivered straight to your inbox.
Busy day? We’ve got you covered. Get FREE daily news, practical insights, opportunities and wellbeing content, carefully curated for busy health and social care professionals. Just enter your details below to get The Daily Briefing delivered straight to your inbox.